RxDoctor Payments Data

Hung Nguyen, MD

Family Medicine · Arlington, TXNPI 1932230273

Payments from drug & device makers

$1,540in general payments, 2019–2025

Across 80 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$274
  • Lilly USA, LLC$271
  • Boehringer Ingelheim$178
  • Bardy Diagnostics, Inc.$112
  • Aurinia Pharma U.S., Inc.$99
  • Novartis$86
  • plus $520 from 19 others

What the payments were for

  • Food & beverage$1,540100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,540 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$21,071
Medicare patients
50
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$76,413
RybelsusSemaglutide31$47,226
ShingrixVaricella-Zoster Ge/As01b/Pf173$37,881
EliquisApixaban16$23,063
VascepaIcosapent Ethyl33$21,428
OzempicSemaglutide17$21,175
QuviviqDaridorexant Hcl11$6,201
Boostrix TdapDiphth,pertuss(Acell),tet Vac78$5,262
Omega-3 Acid Ethyl Esters28$4,411
Esomeprazole Magnesium14$2,127
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$1,705
Atorvastatin Calcium97$1,171
Valsartan32$1,093
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide20$952
Levothyroxine Sodium68$844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$178$76,41367 claims
Novo NordiskRybelsus, Ozempic$274$68,40148 claims
GSKShingrix$52$37,881173 claims
PfizerEliquis$14$23,06316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →